International Clinical Trial: Camrelizumab Plus Risedronate and Chemotherapy for Triple-Negative Breast Cancer: An Exploratory Clinical Study on Mechanisms and Efficacy

Geneva, March 23 -- International Clinical Trials Registry received information related to the study (NCT07471815) titled 'Camrelizumab Plus Risedronate and Chemotherapy for Triple-Negative Breast Cancer: An Exploratory Clinical Study on Mechanisms and Efficacy' on March 10.

Study Type: Interventional

Study Design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Harbin Medical University

Condition: Breast Cancer Triple Negative Breast Cancer

Intervention: Drug: Camrelizumab + Risedronate Sodium + Chemotherapy

Recruitment Status: Not recruiting

Phase: Phase 2

Date of First Enrollment: March 4, 2026

Target Sample Size: 30

Countries of Rec...